Atlas Trials

A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Clinical trial NCT03009344 · COMPLETED

Trial details

NCT number
NCT03009344
Sponsor
Eisai Co., Ltd.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Start date
2017-01-10
Primary completion
2017-07-12
Enrollment
7

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.